Floatz logo

Cis-Diamminedichloroplatinum Ii

Non-Small Cell Lung Carcinoma

Explore 1,128 assets in Non-Small Cell Lung Carcinoma →
Floatz Rating
BB70/100
Confidence
Indicative
v0.2
Sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07622186CT.gov
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
—Not Yet Recruiting———
NCT07495098CT.gov
Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer
—Not Yet Recruiting———
NCT06694454CT.gov
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
—Recruiting———
NCT07486817CT.gov
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
—Recruiting———
NCT07633873CT.gov
SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）
—Not Yet Recruiting———
NCT07642024CT.gov
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
—Not Yet Recruiting———
NCT07609121CT.gov
Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
—Not Yet Recruiting———
NCT07524257CT.gov
Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC
—Not Yet Recruiting———
NCT07279935CT.gov
Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.
—Recruiting———
NCT07365319CT.gov
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
—Recruiting———
Show 473 more trials
NCT07643350CT.gov
Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC
—Not Yet Recruiting———
NCT07554846CT.gov
Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
—Not Yet Recruiting———
NCT07453394CT.gov
QLS5132 Combination Therapy in Advanced Solid Tumors
—Not Yet Recruiting———
NCT07336732CT.gov
Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
—Recruiting———
NCT07418866CT.gov
FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer
—Not Yet Recruiting———
NCT07397338CT.gov
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
—Recruiting———
NCT07383116CT.gov
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer
—Not Yet Recruiting———
NCT07063745CT.gov
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
—Recruiting———
NCT07274384CT.gov
Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial
—Not Yet Recruiting———
NCT06405230CT.gov
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
—Recruiting———
NCT07128199CT.gov
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
—Active Not Recruiting———
NCT07256509CT.gov
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
—Not Yet Recruiting———
NCT06996782CT.gov
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
—Recruiting———
NCT07001618CT.gov
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
—Recruiting———
NCT07100080CT.gov
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
—Recruiting———
NCT07330596CT.gov
QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
—Recruiting———
NCT06793215CT.gov
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
—Recruiting———
NCT07190248CT.gov
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
—Recruiting———
NCT07178795CT.gov
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
—Recruiting———
NCT06946797CT.gov
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
—Active Not Recruiting———
NCT07174908CT.gov
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
—Recruiting———
NCT07082179CT.gov
A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
—Recruiting———
NCT06484491CT.gov
IMPT Dose Escalation for NSCLC (HyDose)
—Recruiting———
NCT07109531CT.gov
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
—Not Yet Recruiting———
NCT07122687CT.gov
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
—Recruiting———
NCT07063329CT.gov
Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive
—Not Yet Recruiting———
NCT07005102CT.gov
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
—Recruiting———
NCT07046923CT.gov
A Study of LY4175408 in Participants With Advanced Cancer
—Recruiting———
NCT07086456CT.gov
Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer
—Recruiting———
NCT06953843CT.gov
Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases
—Recruiting———
NCT06930794CT.gov
A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
—Recruiting———
NCT07052669CT.gov
Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
—Recruiting———
NCT06745882CT.gov
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
—Recruiting———
NCT06963502CT.gov
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
—Not Yet Recruiting———
NCT06943820CT.gov
AK129 Combination Therapy for Advanced Solid Tumors
—Recruiting———
NCT06970782CT.gov
Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure
—Not Yet Recruiting———
NCT06969612CT.gov
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
—Recruiting———
NCT06875310CT.gov
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
—Recruiting———
NCT06944470CT.gov
JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC
—Not Yet Recruiting———
NCT06829459CT.gov
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
—Recruiting———
NCT06939127CT.gov
Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
—Recruiting———
NCT06917079CT.gov
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
—Recruiting———
NCT06868836CT.gov
Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy
—Recruiting———
NCT06927986CT.gov
Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）
—Recruiting———
NCT06726265CT.gov
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
—Active Not Recruiting———
NCT06883136CT.gov
Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients
—Enrolling By Invitation———
NCT06848426CT.gov
Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial
—Not Yet Recruiting———
NCT06772623CT.gov
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
—Recruiting———
NCT06835569CT.gov
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
—Recruiting———
NCT06890182CT.gov
Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC
—Not Yet Recruiting———
NCT07084610CT.gov
Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
—Recruiting———
NCT06672068CT.gov
A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC
—Not Yet Recruiting———
NCT06431633CT.gov
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
—Recruiting———
NCT06939595CT.gov
A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer
—Recruiting———
NCT07005336CT.gov
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
—Active Not Recruiting———
NCT07039656CT.gov
Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy
—Recruiting———
NCT06687369CT.gov
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
—Recruiting———
NCT06621563CT.gov
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
—Recruiting———
NCT06632327CT.gov
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
—Recruiting———
NCT06704724CT.gov
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
—Terminated———
NCT06704620CT.gov
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer
—Not Yet Recruiting———
NCT06746870CT.gov
A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer
—Not Yet Recruiting———
NCT06671379CT.gov
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC
—Active Not Recruiting———
NCT06627647CT.gov
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
—Recruiting———
NCT06659042CT.gov
Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
—Recruiting———
NCT06956001CT.gov
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
—Recruiting———
NCT06594874CT.gov
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
—Not Yet Recruiting———
NCT06711900CT.gov
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
—Recruiting———
NCT06623422CT.gov
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
—Recruiting———
NCT06607185CT.gov
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
—Active Not Recruiting———
NCT06564844CT.gov
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
—Active Not Recruiting———
NCT06561386CT.gov
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
—Recruiting———
NCT06417814CT.gov
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
—Recruiting———
NCT06652048CT.gov
High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI
—Recruiting———
NCT06970639CT.gov
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
—Recruiting———
NCT06463665CT.gov
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
—Recruiting———
NCT06561685CT.gov
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
—Recruiting———
NCT06452277CT.gov
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
—Recruiting———
NCT06574347CT.gov
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
—Recruiting———
NCT06545747CT.gov
Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI
—Recruiting———
NCT06512051CT.gov
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
—Recruiting———
NCT06430437CT.gov
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
—Recruiting———
NCT06161441CT.gov
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
—Active Not Recruiting———
NCT06046495CT.gov
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
—Recruiting———
NCT06514027CT.gov
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
—Not Yet Recruiting———
NCT06475755CT.gov
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
—Not Yet Recruiting———
NCT06447662CT.gov
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
—Recruiting———
NCT06093503CT.gov
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
—Withdrawn———
NCT06382116CT.gov
A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)
—Active Not Recruiting———
NCT06380348CT.gov
JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations
—Not Yet Recruiting———
NCT06299371CT.gov
Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations
—Not Yet Recruiting———
NCT06236438CT.gov
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
—Recruiting———
NCT06008093CT.gov
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
—Active Not Recruiting———
NCT06312137CT.gov
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
—Recruiting———
NCT05116462CT.gov
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
—Active Not Recruiting———
NCT06151574CT.gov
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
—Active Not Recruiting———
NCT06015724CT.gov
Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
—Recruiting———
NCT06357598CT.gov
Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer
—Unknown———
NCT06162221CT.gov
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
—Recruiting———
NCT06110663CT.gov
A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
—Unknown———
NCT06119581CT.gov
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
—Recruiting———
NCT05689671CT.gov
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
—Active Not Recruiting———
NCT06281964CT.gov
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
—Enrolling By Invitation———
NCT06094296CT.gov
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
—Terminated———
NCT06281860CT.gov
Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration
—Unknown———
NCT06091943CT.gov
Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
—Active Not Recruiting———
NCT05948462CT.gov
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
—Withdrawn———
NCT05800015CT.gov
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
—Active Not Recruiting———
NCT05849246CT.gov
The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
—Terminated———
NCT05791097CT.gov
Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.
—Withdrawn———
NCT06139419CT.gov
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
—Active Not Recruiting———
NCT06015503CT.gov
A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
—Active Not Recruiting———
NCT05624996CT.gov
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
—Recruiting———
NCT05751187CT.gov
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients
—Active Not Recruiting———
NCT05870319CT.gov
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
—Active Not Recruiting———
NCT05789082CT.gov
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
—Recruiting———
NCT06212752CT.gov
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
—Active Not Recruiting———
NCT06343064CT.gov
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
—Recruiting———
NCT05767892CT.gov
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
—Not Yet Recruiting———
NCT05633667CT.gov
Study of Novel Treatment Combinations in Patients With Lung Cancer
—Active Not Recruiting———
NCT05577702CT.gov
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
—Completed———
NCT05635708CT.gov
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
—Active Not Recruiting———
NCT05722015CT.gov
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
—Active Not Recruiting———
NCT05597800CT.gov
Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome
—Not Yet Recruiting———
NCT05555732CT.gov
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
—Active Not Recruiting———
NCT05687266CT.gov
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
—Active Not Recruiting———
NCT05198830CT.gov
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
—Recruiting———
NCT05493501CT.gov
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
—Terminated———
NCT05487391CT.gov
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
—Recruiting———
NCT06241807CT.gov
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
—Recruiting———
NCT05609578CT.gov
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
—Recruiting———
NCT05502237CT.gov
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
—Active Not Recruiting———
NCT07632365CT.gov
Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
—Active Not Recruiting———
NCT05543330CT.gov
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
—Recruiting———
NCT05504278CT.gov
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
—Recruiting———
NCT05386888CT.gov
A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
—Completed———
NCT05261399CT.gov
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
—Active Not Recruiting———
NCT05407155CT.gov
Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer
—Active Not Recruiting———
NCT05394233CT.gov
Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC
—Unknown———
NCT05186974CT.gov
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
—Active Not Recruiting———
NCT05351788CT.gov
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
—Recruiting———
NCT05298423CT.gov
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
—Active Not Recruiting———
NCT05061550CT.gov
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
—Recruiting———
NCT05284539CT.gov
Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
—Recruiting———
NCT05226598CT.gov
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
—Completed———
NCT05430802CT.gov
Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE)
—Unknown———
NCT05247684CT.gov
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
—Active Not Recruiting———
NCT05312840CT.gov
Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer
—Completed———
NCT05132985CT.gov
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
—Not Yet Recruiting———
NCT04372927CT.gov
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
—Terminated———
NCT04786964CT.gov
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC
—Terminated———
NCT05003037CT.gov
Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer
—Unknown———
NCT05020457CT.gov
SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.
—Active Not Recruiting———
NCT05015608CT.gov
Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
—Completed———
NCT05012254CT.gov
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases
—Active Not Recruiting———
NCT05014815CT.gov
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
—Completed———
NCT05281406CT.gov
Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
—Recruiting———
NCT05048797CT.gov
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
—Active Not Recruiting———
NCT05104788CT.gov
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
—Recruiting———
NCT04765709CT.gov
Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC
—Terminated———
NCT04816214CT.gov
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy
—Terminated———
NCT05116891CT.gov
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
—Completed———
NCT04989283CT.gov
Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
—Withdrawn———
NCT05055583CT.gov
Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC
—Unknown———
NCT04585490CT.gov
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
—Recruiting———
NCT04491942CT.gov
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
—Active Not Recruiting———
NCT05011487CT.gov
Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
—Recruiting———
NCT04956692CT.gov
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
—Active Not Recruiting———
NCT04846634CT.gov
Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
—Not Yet Recruiting———
NCT04762459CT.gov
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
—Enrolling By Invitation———
NCT04956640CT.gov
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
—Active Not Recruiting———
NCT04611776CT.gov
A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer
—Withdrawn———
NCT04971187CT.gov
Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer
—Terminated———
NCT04870112CT.gov
A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer
—Terminated———
NCT04846452CT.gov
Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC
—Unknown———
NCT04999761CT.gov
AB122 Platform Study
—Recruiting———
NCT04768075CT.gov
Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC
—Completed———
NCT04646837CT.gov
Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models
—Unknown———
NCT04733521CT.gov
A Phase 1/2 Study of SC-43 in Combination With Cisplatin
—Unknown———
NCT04832854CT.gov
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
—Terminated———
NCT04585477CT.gov
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
—Recruiting———
NCT04686305CT.gov
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
—Recruiting———
NCT04809103CT.gov
Intratumoral Cisplatin for Resectable NSCLC
—Completed———
NCT04828395CT.gov
Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer
—Unknown———
NCT04623775CT.gov
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
—Completed———
NCT04982549CT.gov
A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC
—Unknown———
NCT04547504CT.gov
PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %
—Active Not Recruiting———
NCT04606303CT.gov
A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.
—Unknown———
NCT04351555CT.gov
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
—Active Not Recruiting———
NCT04619797CT.gov
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
—Completed———
NCT04646824CT.gov
Almonertinib With Chemotherapy in mEGFR NSCLC
—Unknown———
NCT04517526CT.gov
Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study
—Unknown———
NCT04524689CT.gov
Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
—Terminated———
NCT04586465CT.gov
Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC
—Unknown———
NCT04455594CT.gov
Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC
—Unknown———
NCT04750083CT.gov
HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer
—Unknown———
NCT04526691CT.gov
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
—Active Not Recruiting———
NCT04205812CT.gov
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
—Active Not Recruiting———
NCT04465968CT.gov
Efficacy and Safety of CRT, Durvalumab and Surgery for SST
—Not Yet Recruiting———
NCT05347628CT.gov
Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
—Unknown———
NCT04203511CT.gov
INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)
—Withdrawn———
NCT04222972CT.gov
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
—Terminated———
NCT04470076CT.gov
Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation
—Unknown———
NCT04380636CT.gov
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
—Active Not Recruiting———
NCT04212052CT.gov
Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer
—Completed———
NCT04267848CT.gov
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
—Recruiting———
NCT04389632CT.gov
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
—Recruiting———
NCT04061590CT.gov
Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer
—Withdrawn———
NCT04379635CT.gov
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
—Active Not Recruiting———
NCT04367311CT.gov
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
—Active Not Recruiting———
NCT04092283CT.gov
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
—Active Not Recruiting———
NCT04158440CT.gov
Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC
—Active Not Recruiting———
NCT04328844CT.gov
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
—Active Not Recruiting———
NCT04194944CT.gov
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
—Active Not Recruiting———
NCT04129502CT.gov
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
—Active Not Recruiting———
NCT04198766CT.gov
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
—Active Not Recruiting———
NCT04153734CT.gov
Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC
—Not Yet Recruiting———
NCT04716933CT.gov
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study
—Completed———
NCT04083599CT.gov
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
—Active Not Recruiting———
NCT03991403CT.gov
Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC
—Unknown———
NCT03737994CT.gov
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
—Terminated———
NCT03920839CT.gov
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
—Withdrawn———
NCT03802240CT.gov
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
—Completed———
NCT04035486CT.gov
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
—Active Not Recruiting———
NCT03976323CT.gov
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
—Completed———
NCT03944772CT.gov
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
—Active Not Recruiting———
NCT04840290CT.gov
A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC
—Unknown———
NCT03912389CT.gov
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC
—Unknown———
NCT03945227CT.gov
Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)
—Withdrawn———
NCT03745222CT.gov
A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
—Terminated———
NCT03645928CT.gov
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
—Terminated———
NCT03840902CT.gov
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
—Terminated———
NCT03840915CT.gov
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
—Completed———
NCT03829319CT.gov
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
—Completed———
NCT04287894CT.gov
Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment
—Terminated———
NCT03819465CT.gov
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
—Active Not Recruiting———
NCT03631199CT.gov
Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
—Terminated———
NCT03775486CT.gov
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
—Active Not Recruiting———
NCT03800134CT.gov
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
—Active Not Recruiting———
NCT03058094CT.gov
A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI
—Withdrawn———
NCT03672136CT.gov
Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients
—Unknown———
NCT03664024CT.gov
Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)
—Completed———
NCT03631784CT.gov
A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)
—Completed———
NCT03671538CT.gov
Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin
—Unknown———
NCT03659578CT.gov
Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer
—Completed———
NCT03663205CT.gov
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
—Completed———
NCT03574402CT.gov
Phase II Umbrella Study Directed by Next Generation Sequencing
—Unknown———
NCT03515837CT.gov
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
—Completed———
NCT03485209CT.gov
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
—Active Not Recruiting———
NCT03574649CT.gov
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
—Withdrawn———
NCT03520686CT.gov
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
—Terminated———
NCT03509012CT.gov
Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors
—Completed———
NCT03425643CT.gov
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
—Active Not Recruiting———
NCT03456063CT.gov
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
—Completed———
NCT03381066CT.gov
A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.
—Unknown———
NCT03519971CT.gov
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
—Active Not Recruiting———
NCT03169738CT.gov
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
—Withdrawn———
NCT03413358CT.gov
Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid
—Unknown———
NCT03317496CT.gov
Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies
—Terminated———
NCT03178552CT.gov
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
—Active Not Recruiting———
NCT03267316CT.gov
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
—Completed———
NCT03215706CT.gov
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
—Completed———
NCT03201146CT.gov
Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC
—Unknown———
NCT03158129CT.gov
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
—Completed———
NCT03138889CT.gov
Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors
—Terminated———
NCT03164616CT.gov
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
—Active Not Recruiting———
NCT03088540CT.gov
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
—Completed———
NCT03064854CT.gov
PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
—Terminated———
NCT02987998CT.gov
Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC
—Terminated———
NCT03141359CT.gov
Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC
—Active Not Recruiting———
NCT02964689CT.gov
Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.
—Completed———
NCT03123445CT.gov
Endostar First-line Treatment of Advanced NSCLC
—Unknown———
NCT02864251CT.gov
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy
—Completed———
NCT02998528CT.gov
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
—Completed———
NCT03053856CT.gov
Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients
—Unknown———
NCT03003962CT.gov
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
—Active Not Recruiting———
NCT03023423CT.gov
A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
—Completed———
NCT02944396CT.gov
Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
—Completed———
NCT03062800CT.gov
Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)
—Unknown———
NCT03374280CT.gov
Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC
—Unknown———
NCT02897375CT.gov
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
—Completed———
NCT02579564CT.gov
Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients
—Unknown———
NCT03269162CT.gov
Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection
—Unknown———
NCT02862457CT.gov
Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)
—Completed———
NCT02795884CT.gov
Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation
—Withdrawn———
NCT02766348CT.gov
Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients
—Unknown———
NCT02657434CT.gov
A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
—Completed———
NCT02919462CT.gov
Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression
—Terminated———
NCT02662634CT.gov
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
—Withdrawn———
NCT03950674CT.gov
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study
—Completed———
NCT02651441CT.gov
D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)
—Unknown———
NCT02578680CT.gov
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)
—Completed———
NCT02537561CT.gov
Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
—Withdrawn———
NCT02542293CT.gov
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
—Active Not Recruiting———
NCT02326285CT.gov
Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB
—Terminated———
NCT02486718CT.gov
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
—Active Not Recruiting———
NCT02576574CT.gov
Avelumab in First-line NSCLC (JAVELIN Lung 100)
—Completed———
NCT02643407CT.gov
Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer
—Unknown———
NCT02535325CT.gov
Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer
—Completed———
NCT02495896CT.gov
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
—Active Not Recruiting———
NCT01971489CT.gov
Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
—Withdrawn———
NCT02477826CT.gov
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
—Completed———
NCT02577341CT.gov
Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer
—Completed———
NCT02607592CT.gov
A Prospective Multi-center Phase III Randomized Controlled Trial
—Unknown———
NCT02453282CT.gov
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
—Active Not Recruiting———
NCT02409342CT.gov
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
—Completed———
NCT02603003CT.gov
the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs
—Completed———
NCT02489903CT.gov
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
—Completed———
NCT02337530CT.gov
Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC
—Completed———
NCT02409355CT.gov
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
—Terminated———
NCT02667743CT.gov
Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC
—Unknown———
NCT02412371CT.gov
A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)
—Terminated———
NCT02513355CT.gov
Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research
—Unknown———
NCT02347917CT.gov
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
—Completed———
NCT02276560CT.gov
Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC
—Terminated———
NCT01631357CT.gov
Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer
—Completed———
NCT02972216CT.gov
Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy
—Completed———
NCT02264990CT.gov
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
—Completed———
NCT02194738CT.gov
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
—Active Not Recruiting———
NCT02142738CT.gov
Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
—Completed———
NCT02083679CT.gov
Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer
—Terminated———
NCT01702714CT.gov
A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease
—Withdrawn———
NCT02194556CT.gov
Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC
—Unknown———
NCT02119650CT.gov
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
—Terminated———
NCT01993810CT.gov
Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
—Active Not Recruiting———
NCT02031601CT.gov
Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer
—Unknown———
NCT01982955CT.gov
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
—Completed———
NCT02001896CT.gov
Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation
—Unknown———
NCT02009449CT.gov
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
—Completed———
NCT01822496CT.gov
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
—Terminated———
NCT02001168CT.gov
Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB
—Unknown———
NCT02728492CT.gov
Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
—Completed———
NCT01828099CT.gov
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
—Completed———
NCT02316327CT.gov
Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab
—Completed———
NCT01783197CT.gov
Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC
—Completed———
NCT01902875CT.gov
Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy
—Unknown———
NCT01840579CT.gov
Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)
—Completed———
NCT01809210CT.gov
Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer
—Completed———
NCT01836341CT.gov
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
—Withdrawn———
NCT01820754CT.gov
Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
—Completed———
NCT01788566CT.gov
A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer
—Completed———
NCT01752023CT.gov
A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.
—Terminated———
NCT01742767CT.gov
Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC
—Unknown———
NCT01639001CT.gov
A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
—Completed———
NCT01642251CT.gov
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
—Completed———
NCT01714037CT.gov
A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]
—Terminated———
NCT01655225CT.gov
A Study of LY3023414 in Participants With Advanced Cancer
—Completed———
NCT01641575CT.gov
A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin
—Terminated———
NCT01562210CT.gov
Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC
—Completed———
NCT01519804CT.gov
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
—Completed———
NCT01496742CT.gov
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
—Completed———
NCT01560195CT.gov
A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy
—Unknown———
NCT01544179CT.gov
A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone
—Completed———
NCT01502202CT.gov
Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers
—Unknown———
NCT01560104CT.gov
A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
—Completed———
NCT01454102CT.gov
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
—Completed———
NCT01810367CT.gov
ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC
—Completed———
NCT03117335CT.gov
Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
—Completed———
NCT01405079CT.gov
Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation
—Unknown———
NCT01386385CT.gov
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
—Active Not Recruiting———
NCT01669707CT.gov
Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)
—Unknown———
NCT01336842CT.gov
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
—Completed———
NCT01232452CT.gov
A Study in Non-Small Cell Lung Cancer
—Completed———
NCT02549261CT.gov
Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer
—Unknown———
NCT01393080CT.gov
Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients
—Unknown———
NCT01874678CT.gov
A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer
—Completed———
NCT01139775CT.gov
A Study in Non Small Cell Lung Cancer
—Completed———
NCT01282333CT.gov
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
—Terminated———
NCT01424709CT.gov
Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer (NSCLC)
—Unknown———
NCT01185847CT.gov
A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
—Completed———
NCT01160744CT.gov
A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
—Completed———
NCT02497118CT.gov
Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC
—Completed———
NCT00907504CT.gov
Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer
—Withdrawn———
NCT01109524CT.gov
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer
—Completed———
NCT01356368CT.gov
Customizing First Line Chemotherapy in Advanced Non-Small Cell Lung Cancer
—Terminated———
NCT01086254CT.gov
SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer
—Completed———
NCT01121393CT.gov
BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
—Completed———
NCT00966914CT.gov
Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin
—Completed———
NCT01118676CT.gov
Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer
—Completed———
NCT06585189CT.gov
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]
—Completed———
NCT06607393CT.gov
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]
—Completed———
NCT01077713CT.gov
A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer
—Completed———
NCT00981058CT.gov
First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin
—Completed———
NCT01088906CT.gov
Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC
—Terminated———
NCT01192243CT.gov
Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients
—Unknown———
NCT00982111CT.gov
First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin
—Completed———
NCT01058759CT.gov
Taxotere-Enoxaparin-(ENOXA)-Study
—Terminated———
NCT01017874CT.gov
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
—Completed———
NCT00974584CT.gov
A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
—Completed———
NCT00995761CT.gov
Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC)
—Completed———
NCT00985855CT.gov
Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer
—Completed———
NCT01028729CT.gov
A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)
—Unknown———
NCT00949650CT.gov
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
—Completed———
NCT00961415CT.gov
AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer
—Completed———
NCT00994097CT.gov
NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer
—Completed———
NCT00871403CT.gov
Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer
—Completed———
NCT01209520CT.gov
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
—Completed———
NCT00799240CT.gov
MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer
—Completed———
NCT00832117CT.gov
Phase I Combination Ixabepilone + Cisplatin
—Completed———
NCT00887315CT.gov
The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)
—Terminated———
NCT00942825CT.gov
Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)
—Completed———
NCT00883779CT.gov
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
—Completed———
NCT00867009CT.gov
A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer
—Completed———
NCT00776698CT.gov
A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
—Completed———
NCT00775385CT.gov
TAilored Post-Surgical Therapy in Early Stage NSCLC
—Completed———
NCT00870870CT.gov
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
—Completed———
NCT01356303CT.gov
Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer
—Suspended———
NCT00901537CT.gov
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer
—Terminated———
NCT00842712CT.gov
Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)
—Completed———
NCT00820755CT.gov
Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)
—Completed———
NCT00599755CT.gov
Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3)
—Completed———
NCT01019798CT.gov
Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer
—Unknown———
NCT01687439CT.gov
Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)
—Completed———
NCT00828841CT.gov
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
—Completed———
NCT00735904CT.gov
Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer
—Completed———
NCT00773188CT.gov
A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.
—Completed———
NCT00794417CT.gov
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
—Terminated———
NCT00874328CT.gov
A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
—Unknown———
NCT00680940CT.gov
A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer
—Completed———
NCT00771563CT.gov
Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES)
—Completed———
NCT00678977CT.gov
A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors
—Completed———
NCT00620269CT.gov
Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III
—Unknown———
NCT00617656CT.gov
Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma
—Terminated———
NCT00705549CT.gov
Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer
—Terminated———
NCT02889666CT.gov
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
—Recruiting———
NCT00545948CT.gov
Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer
—Terminated———
NCT00560573CT.gov
Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer
—Completed———
NCT00535275CT.gov
NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy
—Terminated———
NCT00417248CT.gov
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
—Terminated———
NCT00478699CT.gov
Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)
—Completed———
NCT00455572CT.gov
Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer
—Terminated———
NCT00409006CT.gov
Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers
—Completed———
NCT00449033CT.gov
A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)
—Completed———
NCT00633568CT.gov
Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer
—Terminated———
NCT00413283CT.gov
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
—Completed———
NCT00379717CT.gov
Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
—Unknown———
NCT00496275CT.gov
Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC
—Completed———
NCT01998919CT.gov
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
—Completed———
NCT00329472CT.gov
Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-small Cell Lung Cancer
—Withdrawn———
NCT00497315CT.gov
Evaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
—Completed———
NCT00415818CT.gov
Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer
—Completed———
NCT00529100CT.gov
Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer
—Completed———
NCT00434668CT.gov
Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer
—Completed———
NCT00254904CT.gov
Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC
—Terminated———
NCT00326378CT.gov
Efficacy Study of Additional Chemotherapy After Concurrent Chemoradiation in Non-small Cell Lung Cancer
—Completed———
NCT00130780CT.gov
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
—Completed———
NCT00291850CT.gov
Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC
—Terminated———
NCT00424853CT.gov
ADVANCED Phase II Trial of Weekly vs 3 Weekly Docetaxel and Cisplatin Followed by Gemcitabine in Non-small-cell Lung Cancer (NSCLC)
—Completed———
NCT00271323CT.gov
Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients
—Terminated———
NCT00232206CT.gov
Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer
—Terminated———
NCT00683514CT.gov
Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer
—Completed———
NCT00172380CT.gov
Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III
—Completed———
NCT00806923CT.gov
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
—Completed———
NCT02127372CT.gov
Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571
—Terminated———
NCT00148798CT.gov
Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)
—Completed———
NCT00582634CT.gov
Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer
—Completed———
NCT00333294CT.gov
Phase II Iressa + Irradiation Followed by Chemo in NSCLC
—Completed———
NCT00077883CT.gov
TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
—Completed———
NCT00622349CT.gov
Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer
—Completed———
NCT00082472CT.gov
Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)
—Unknown———
NCT00055757CT.gov
Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
—Completed———
NCT00682383CT.gov
Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)
—Completed———
NCT00069875CT.gov
A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer
—Completed———
NCT00198367CT.gov
Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)
—Completed———
NCT00385606CT.gov
Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC
—Completed———
NCT00178698CT.gov
Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors
—Unknown———
NCT00425191CT.gov
Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.
—Completed———
NCT00401492CT.gov
MILES-02: Study of Chemotherapy Treatment and Toxicity in Elderly Patients With Advanced Non Small Cell Lung Cancer
—Completed———
NCT00148395CT.gov
Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.
—Completed———
NCT00198432CT.gov
Chemoradiotherapy of NSCLC Stage IIIB
—Completed———
NCT00020709CT.gov
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
—Completed———
NCT00198354CT.gov
Stage I/II NSCLC Perioperative Chemotherapy
—Completed———
NCT00005838CT.gov
Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Non-Small Cell Lung Carcinoma

AssetSponsorPhaseRating
Cis-Diamminedichloroplatinum Ii (this asset)Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.ApprovedBB · 70
NecitumumabJonsson Comprehensive Cancer CenterP3BBB
GlumetinibShanghai JMT-Bio Inc.P3BBB
VeliparibAbbVieP3BBB
d-0316Betta Pharmaceuticals Co., Ltd.P2/3BBB
IcotinibThe First Affiliated Hospital of Guangzhou Medical UniversityP4BBB
ZoledronateChia Tai Tianqing Pharmaceutical Group Co., Ltd.P4BBB
OnartuzumabHoffmann-La RocheP3BBB
AvitinibHangzhou ACEA Pharmaceutical Research Co., Ltd.P3BBB

+42 more in the Non-Small Cell Lung Carcinoma cohort

Other indications for Cis-Diamminedichloroplatinum Ii

IndicationSponsorPhaseRating
Squamous Cell Lung Carcinoma—P4BBB · 78
Primary Peritoneal Carcinoma—P3BBB · 77
Adenocarcinoma—P4BBB · 76

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Cis-Diamminedichloroplatinum Ii in Non-Small Cell Lung Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/cis-diamminedichloroplatinum-ii-non-small-cell-lung-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →